Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Fusion glycoprotein F0

Fusion glycoprotein F0

Brief Information

Name:Respiratory syncytial virus F protein
Target Synonym:Protein F,F,Fusion glycoprotein F0
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Synonym Name

Fusion glycoprotein F0


Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Respiratory syncytial virus immune globulin RSV-IGIV Approved Medimmune RespiGam Canada Respiratory Syncytial Virus Infections Medimmune Llc 1996-01-01 Respiratory Syncytial Virus Infections Details
Nirsevimab Anti-RSV MAb-YTE; Anti-RSV-mAb-D25; SP-0232; MEDI-8897 Approved Aimm Therapeutics, Sanofi, MedImmune Inc Beyfortus EU Respiratory Syncytial Virus Infections Astrazeneca Ab 2022-10-31 Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections Details
Palivizumab ABT-315; MEDI-493 Approved Abbvie Inc, Medimmune Llc Synagis Japan Respiratory Syncytial Virus Infections Abbvie Inc 1998-06-19 Bronchopulmonary Dysplasia; Respiratory Syncytial Virus Infections; Heart Defects, Congenital; Premature Birth; Infant, Premature, Diseases Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Motavizumab biosimilar (MedImmune) MEDI-557 Medimmune Llc Details
Motavizumab MEDI-524 Medimmune Llc Details
CPI-RSV-F Vaccine BLB-201 Phase 1 Clinical Blue Lake Biotechnology Inc Respiratory Syncytial Virus Infections Details
Ziresovir RO-0529; AK-0529 Phase 3 Clinical F. Hoffmann-La Roche Ltd Respiratory Syncytial Virus Infections Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message